NEW YORK, NY--(MARKET WIRE)--Jul 31, 2007 -- Chembio Diagnostics, Inc. (OTC BB:CEMI.OB - News) announced today it has signed an initial research and development collaboration with Pall Corporation employing Chembio’s new Dual Path Platform (DPP(TM)). Pall Corporation has a number of potential applications for DPP(TM) although the initial collaboration will be focused on the feasibility of one such application. Pall selected DPP(TM) because of its unique functional design that could facilitate high levels of analyte detection capability.
